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Abstract
Introduction The breast microenvironment can either retard or
accelerate the events associated with progression of latent
cancers. However, the actions of local physiological mediators
in the context of breast cancers are poorly understood.
Serotonin (5-HT) is a critical local regulator of epithelial
homeostasis in the breast and other organs. Herein, we report
complex alterations in the intrinsic mammary gland serotonin
system of human breast cancers.
Methods Serotonin biosynthetic capacity was analyzed in
human breast tumor tissue microarrays using
immunohistochemistry for tryptophan hydroxylase 1 (TPH1).
Serotonin receptors (5-HT1-7) were analyzed in human breast
tumors using the Oncomine database. Serotonin receptor
expression, signal transduction, and 5-HT effects on breast
cancer cell phenotype were compared in non-transformed and
transformed human breast cells.
Results In the context of the normal mammary gland, 5-HT acts
as a physiological regulator of lactation and involution, in part by
favoring growth arrest and cell death. This tightly regulated 5-HT
system is subverted in multiple ways in human breast cancers.
Specifically, TPH1 expression undergoes a non-linear change
during progression, with increased expression during malignant
progression. Correspondingly, the tightly regulated pattern of 5-
HT receptors becomes dysregulated in human breast cancer
cells, resulting in both ectopic expression of some isoforms and
suppression of others. The receptor expression change is
accompanied by altered downstream signaling of 5-HT
receptors in human breast cancer cells, resulting in resistance
to 5-HT-induced apoptosis, and stimulated proliferation.
Conclusions Our data constitutes the first report of direct
involvement of 5-HT in human breast cancer. Increased 5-HT
biosynthetic capacity accompanied by multiple changes in 5-HT
receptor expression and signaling favor malignant progression
of human breast cancer cells (for example, stimulated
proliferation, inappropriate cell survival). This occurs through
uncoupling of serotonin from the homeostatic regulatory
mechanisms of the normal mammary epithelium. The findings
open a new avenue for identification of diagnostic and
prognostic markers, and valuable new therapeutic targets for
managing breast cancer.
Introduction
Evolution in cancers is a convergent phenomenon, during
which heterogeneous genetic and epigenetic changes lead to
similar ultimate tumor phenotypes. The essential phenotype of
epithelial cancers (e.g., breast, liver, pancreas, prostate, and
so on) includes: self-sufficiency for growth signals, insensitivity
to growth inhibition, evasion of programmed cell death, appar-
ently limitless replicative potential, sustained angiogenesis,Page 1 of 17
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phenotypes presents numerous prevention and treatment
challenges because of the ability of cancer cells to exploit a
variety of normal physiological processes out of context. In this
study, we report extensive modifications of the recently-dis-
covered mammary serotonin (5-hydroxytryptamine, 5-HT) sys-
tem [5-9] in human breast cancers. This is the first account
illustrating direct involvement of 5-HT in breast cancers, and
shows that an important homeostatic signal is subverted by
cancer cells, yielding paradoxical effects on growth and apop-
tosis.
Serotonin is a monoamine hormone and neurotransmitter that
has been evolutionarily conserved, with functions stretching
across the animal and plant phyla [10]. Although parochially
known and studied as a neurotransmitter, with critical cogni-
tive and behavioral functions in humans, 5-HT has numerous
important peripheral functions in the gut, vasculature, immune
system, and at wound sites [11-16]. Serotonin is synthesized
in a two-step reaction from the amino acid L-tryptophan. The
first and rate-limiting step in 5-HT synthesis is catalyzed by
tryptophan hydroxylase (TPH), which is represented by neuro-
nal (TPH2) and non-neuronal (TPH1) isoforms. Serotonin
exerts its actions through a repertoire of greater than 15 differ-
ent receptor proteins, belonging to seven discreet families. Six
of the families of 5-HT receptors are G-protein-coupled,
including Gi: 5-HT1, Gs: 5-HT4,6,7, and Gq/11: 5-HT2,5. 5-HT3 is
uniquely a ligand-gated cation channel, related to the nicotinic
acetylcholine receptor. Another major player within the 5-HT
system is the 5-HT reuptake transporter (SERT), which is
involved in the uptake and clearance of extracellular 5-HT.
Mammary epithelial homeostatic mechanisms ensure normal
tissue function during dramatic changes associated with preg-
nancy, lactation and involution. Serotonin is an integral part of
this epithelial homeostatic system. In part, breast cancers arise
through dysregulation of epithelial homeostatic systems
[17,18].
Regulation of epithelial homeostasis by 5-HT is not exclusive
to the mammary epithelium. Serotonin has been implicated in
epithelial homeostasis of the lung, pancreas, liver and pros-
tate. Moreover, dysregulation of 5-HT systems in these epithe-
lia are associated with various pathologies, including cancer
progression [19-29]. Consequently, alteration of local 5-HT
signaling may be a common feature of cancer progression in
epithelial tumors.
In these studies, we present the first analysis of the mammary
5-HT system in human breast cancer. Our results show exten-
sive 5-HT signal modifications contributing to the cancer phe-
notype. These results provide a new theoretical framework for
studying 5-HT signaling in a variety of epithelial cancers.
Materials and methods
Subjects
Primary human mammary epithelial cells (pHMEC), obtained
from reduction mammoplasty under Institutional Review Board
approval, were a generous gift from Eric R. Hugo at The Uni-
versity of Cincinnati; cell lines and anonymous tissue microar-
ray specimens purchased from the National Cancer Institute
were considered to be exempt. The research carried out in this
article is in compliance with the Declaration of Helsinki.
Cells and media
Primary human mammary epithelial cells (pHMEC) were pre-
pared using a modification of previously described protocol
[30]. Briefly, excised human mammary tissue was finely
minced, transferred to conical tubes, and digested overnight
at 37°C in M199 media containing 2.5 mg/ml BSA (Sigma-
Aldrich, St. Louis, MO, USA), 0.1% collagenase type III (Wor-
thington Biochemical Corporation, Lakewood, NJ, USA) and
antibiotic-antimycotic (Invitrogen, Carlsbad, CA, USA).
Digested tissue was pelleted by centrifugation, washed in
phosphate buffered saline (PBS), and either plated in the
pHMEC media (see below) or frozen back for later use.
All the cell lines used in the aforementioned studies were pro-
cured from the American Type Culture Collection (ATCC), and
used within 10 passages after acquisition. MCF10A media
consisted of the following: DMEM-F12 50:50 (Invitrogen) sup-
plemented with 5% horse serum, 2 mM L-glutamine, 10 μg/ml
insulin (Sigma-Aldrich), 20 ng/ml EGF (Upstate Biotechnol-
ogy, Waltham, MA, USA) 0.5 μg/ml hydrocortisone and antibi-
otic/antimycotic (Invitrogen). pHMEC media contained
DMEM-F12 50:50, 5% FBS (Hyclone, Logan, UT, USA), insu-
lin (Sigma-Aldrich), hydrocortisone (Sigma-Aldrich), EGF
(Upstate), 1 ng/ml cholera toxin (Sigma-Aldrich) (except
where noted) and antibiotic-antimycotic (Invitrogen). MDA-
MB-231 cells were cultured in DMEM (Invitrogen) supple-
mented with 10% FBS, L-glutamine and antibiotic-antimycotic
(Invitrogen). T47D cells were grown in same media as MDA-
MB-231 with the addition of 5 μg/ml of insulin. MCF7 cells
were grown in media consisting of DMEM-F12 50:50 (Invitro-
gen) supplemented with 10% FBS, L-glutamine, 1 mM sodium
pyruvate (Invitrogen), 1× concentration of non-essential amino
acids (Invitrogen), and antibiotic-antimycotic (Invitrogen).
Immunohistochemistry and immunofluroscence
Paraformaldehyde fixed paraffin embedded mouse mammary
gland sections and tissue microarray sections were depar-
affinzed in xylene and rehydrated in decreasing concentrations
of ethanol from 100% to 50%. Endogenous peroxidases were
blocked by incubation in 3% H2O2 at room temperature for 30
min. Antigen retrieval was performed using borate buffer pH =
8.5 (80 mM boric acid, 20 mM sodium borate) in a microwave
(60% power) twice for 5 min. Sections were then permeabi-
lized using 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 30
min followed by normal serum blocking for 1 h at room temper-Page 2 of 17
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1:100 Abcam, Cambridge, MA, USA) overnight at 4°C in a
humid chamber. The immune reaction was visualized using
HRP-conjugated secondary antibody (Sigma-Aldrich) and
ABC-DAB system (Zymed, S. San Francisco, CA, USA; and
Vector Labs, Burlingame, CA, USA, respectively).
Cells grown on coverslips were fixed in 4% paraformaldehyde.
Cells were permeabilized in 0.1% Triton X-100, incubated in
borate buffer overnight at 75°C and incubated in primary anti-
bodies overnight at 4°C. Images were collected using a Zeiss
LSM510 Confocal Microscope, Göttingen, Germany) using
the Zeiss LSM Image Software version 3.5, Munich, Germany)
RT-PCR and Western blot
Total cellular RNA was extracted using TRI-REAGENT (Molec-
ular Research Center, Inc., Cincinnati, OH, USA) according to
the manufacturer's instructions. Two μg of RNA was sub-
jected to reverse transcription by standard methods. One μl
cDNA was used for 25 μl PCR reactions. For primer informa-
tion, please see Table S1 in Additional data file 1.
Cellular protein extracts were prepared using the Cell Lysis kit
(Cell Signaling Technology, Boston, MA, USA) as per the
manufacturer's instructions. Proteins were quantified using
Lowry assay and equal amounts were separated on SDS-
PAGE gel. After transferring the proteins to nitrocellulose
membrane, the specific proteins were visualized using specific
antibodies and detected using HRP tagged secondary anti-
bodies.
Proliferation assay and Trypan blue assay
After experimental treatments, cell proliferation was measured
by colorimetric assay based on cleavage of a tetrazolium salt
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) by mitochondrial dehydro-
genase enzyme present in proliferating cells (Cell titer 96 -
Promega, Madison, WI, USA). For trypan blue experimental
procedures, the cells were gently trypsinized and re-sus-
pended in 0.2% trypan blue solution and counted using a
hemocytometer.
Tissue microarray
Human breast cancer tissue microarrays were purchased from
The National Cancer Institute (Bethesda, MD, USA [31]. The
array has 288 cores in quadruplicate with tissue matched con-
trols. A modified histochemical-score (H-score) [32,33] sys-
tem was used to evaluate the breast cancer tissue
microarrays. An H-score comprises of a semi-quantitative
assessment of both the intensity of staining and percentage of
positive mammary epithelial cells. For intensity, a score of 0 to
3, corresponding to negative, weak, positive and strong posi-
tive was recorded blindly by two independent observers with
final scores resulting in an average. It was not necessary to
correct the staining intensities to account for the percentage
of positive cells because of uniform epithelial staining within
given specimens.
Statistics
Each experiment in cultured cells and tissues was replicated
three or four times, and representative results are shown in fig-
ures. Differences in means were tested by ANOVA with
Tukey's post-hoc test for multiple groups, and Student's T-test
or an equivalent non parametric test (Mann-Whitney U test) for
comparisons of two means. Significance was accepted for P
< 0.05.
Results
Elevated TPH1 in human breast cancer cells
TPH1 catalyzes the first and the rate-limiting step in 5-HT bio-
synthesis. We have previously shown that TPH1 is expressed
in the mammary gland and TPH1 expression directly correlates
with 5-HT production [5,6]. We therefore addressed the ques-
tion of whether there were any changes in 5-HT synthetic
capacity of breast cancer cells. Toward this end, we analyzed
TPH1 mRNA levels by reverse-transcriptase-couple polymer-
ase chain reaction (RT-PCR) in different human breast cancer
cells (MCF7, MDA-MB-231 and T47D), and compared them
to that of non-transformed human mammary epithelial cells
(MCF10A). The mRNA levels of TPH1 were elevated more
than two-fold in MDA-MB-231 and T47D cells compared to
that of MCF10A cells (Figure 1A). The TPH1 protein was ana-
lyzed by western blot in extracts of these cells and was signif-
icantly elevated not only in MDA-MB-231 and T47D, but also
in MCF7 cells, demonstrating that 5-HT biosynthetic capacity
was increased in all breast cancer cell lines tested, with the
highest level of expression occurring in MDA-MB-231 cells
(Figure 1B). This was contrary to what occurred in MCF10A
cells, where TPH1 protein was near the lower limit of detection
by western blotting (Figure 1B). An additional factor that reg-
ulates cellular exposure to 5-HT is SERT, which pumps 5-HT
back into the cells contributing to the recycling and controlling
the extracellular concentration of 5-HT. We assessed SERT
protein levels and found them to be similar among these cell
lines [see Figure S1 in Additional data file 1].
Nonlinear association of TPH1 with breast cancer 
progression
To gain insight into the possible association between altered
5-HT synthesis and breast cancer progression in actual human
tumors, we analyzed TPH1 in histological specimens. The
specimens used were human breast cancer tissue microarrays
acquired from The National Cancer Institute Cooperative
Breast Cancer Tissue Resource [31]. Quadruplicate samples
of 288 cores comprised the array, which included both tissue-
matched non-cancer and non-diseased controls, along with
cell line controls. Figure 2A shows a representative section of
normal human breast tissue from an array at two different mag-
nifications, stained for TPH1. In normal breast tissue the epi-
thelium was dispersed in an orderly fashion within the stroma,Page 3 of 17
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blood vessel-associated cells were also positive for TPH1
within the stroma. A modified H-score [34,35] was used by
blinded examiners to score the stained tissues. Sections were
scored on a scale of 0 to 3 with respect to TPH1 staining sep-
arately within epithelia and stroma, using a key generated from
among the array sections [see Figure S2 in Additional data file
1]. Cores of cell lines on the array (MCF7 and T47D) validated
the scoring for TPH1. Similar to the expression pattern we had
seen previously in the cell lines (Figure 1), TPH1 staining inten-
sity was significantly elevated in the cancer cell lines, com-
pared with normal breast tissue (Figure 2B).
The tissue specimens on the array were all from primary tumor
sites, and were scored based on a variety of pathological cri-
teria. An obvious and clinically meaningful characterization is
reproductive steroid receptor (estrogen receptor (ER) and
progesterone receptor (PR)) status. Levels of TPH1 were
lower in ER negative cases, compared with ER positive cases.
There was no difference in TPH1 levels associated with PR
status of the breast cancers (Figure 2C and 2D, respectively).
Segregating the cases crudely according to tumor size and
according to T-stage (another size-based classification)
showed an inverse relationship between tumor size (>20 mm)
and TPH1 staining [see Figure S3 in Additional data file 1].
When the breast cancer cases were sorted according to inva-
sion and progression criteria, TPH1 staining showed a set of
nonlinear relationships (Figure 3). Staining for TPH1 was
lower in locally-invasive (IN+) cases compared with non-inva-
sive samples (NI), which included both normal tissue and duc-
tal carcinoma in situ (DCIS). However, TPH1 was high in
cases of tumors with distant metastases (IN-Mets) (Figure
3A). The relationship of TPH1 staining to progression was
clearest among samples sorted according to N-stage (extent
of lymph node involvement) (Figure 3B). Staining for TPH1
was significantly decreased in the N1 staged tumors (one to
three ipsilateral nodes). However, with progression to N1a/b
stage (micrometastases to four or more nodes, including
extension beyond the node capsule) and higher stages (N2/3),
the TPH1 staining was elevated. Representative core sections
from each sorted category are depicted in Figure 3C.
5-HT receptor expression in association with breast 
cancer progression
To determine the expression of 5-HT receptor mRNA profiles,
we performed a comprehensive analysis by RT-PCR (Figure
4). In addition to HTR7, which has been studied in detail in the
breast [6,7], we report for the first time the expression of
HTR1D, 2B and 3A in an untransformed cell line and primary
human mammary epithelial cells (MCF10A and pHMEC) (Fig-
ure 4). The HTR1D and 2B were also present in all breast can-
cer cells tested and, using human hypothalamus as the
reference level, expression in the cancer cells was elevated
compared to the untransformed cells (Figure 4Bi and 4Biv).
Among the receptor isoforms that were expressed differen-
tially in breast cancer cell lines, HTR3A was markedly down-
regulated in all of the cancer lines (Figure 4A and 4Bvi). Three
receptor types were upregulated in MCF7 to levels that were
Figure 1
TPH1 expression in non-transformed and breast cancer cells. (A) Bar graphs representing TPH1 mRNA levels in indicated cell lines as detected by 
semi-quantitative RT - PCR reactions and normalized to GAPDH. Shown below is a representative picture of resulting PCR reactions. (B) Bar 
graphs and electophoretic bands showing TPH1 protein levels in the extracts of indicated cells normalized to β-actin. Error bars in (A) and (B) repre-
sent ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA) in comparison to MCF10A cells.Page 4 of 17
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4Bv). MDA-MB-231 expressed 1F, and T-47D expressed both
1F and 2C at modest levels relative to the brain (Figure 4B).
No detectable transcripts for HTR1A, 1B, 2A, 4, 5A and 6
were found in the untransformed (MCF10A and pHMECs) or
breast cancer cells (MCF7, T47D and MDA-MB-231) (Figure
4A) and [see Figure S4 in Additional data file 1]. HTR7 was
expressed in MCF10A [6,7], pHMEC and MDA-MB-231 cells.
In contrast, MCF7 and T47D, both of which are ER positive
cancer cells, lacked any detectable HTR7 transcript (Figure
4A).
To address the question of 5-HT receptor profiles in breast
cancers, we examined expression using the Oncomine data-
Figure 2
Changes in TPH1 signal in human breast tumors. (A) Representative image of normal human breast tissue (BT) from the tissue microarray stained 
for TPH1 (brown) and counterstained with hematoxylin. A corresponding no primary antibody control section is depicted on the bottom left. Magni-
fied image shows details of epithelial staining and occasional positive cells in stroma. (B-D) Results depicting quantification of TPH1 immunostain-
ing from blindly scored tissue microarray sections. The section scores for TPH1 were sorted as per human cancer cell line core (B), estrogen 
receptor (ER) status (C) and progesterone receptor (PR) status (D). TPH1 staining was reduced in ER negative tumors, but unaffected by PR status. 
Error bars represent ± SEM. *P < 0.05 in comparison with normal BT for (A).Page 5 of 17
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receptor gene expression (Table 1). Among all of the receptor
isoforms, HTR1B, 1D, 1F, 2A, 2B, 2C, 3, 4, 5A, 7 were found
to be expressed in breast tissues (cancer and other). Of these
receptors, the expression levels of HTR1D, 2A and 3 were
unchanged in the archived studies (data not shown). The
HTR1D pattern was in accord with the breast cancer cell lines
(Table 1). HTR1B and 2A were not expressed in either
pHMEC or established breast cell lines (Figure 4), which
implies that expression in tumor specimens represents the
presence of stromal or vascular elements, which typically
express HTR1B and 2A in smooth muscle cells [38,39].
A significant subset of 5-HT receptor mRNAs (HTR1F, 2B, 4
and 7), were significantly decreased in ER negative tumors,
relative to ER positive tumors (Table 1). These observations
Figure 3
Nonlinear association between TPH1 and cancer progression. (A-B) Results depicting quantification of TPH1 immunostaining from blindly scored 
tissue microarray sections. Data were sorted based on the indicated criteria. Data were analyzed by one-way ANOVA with P-values as noted in com-
parison with NI for (A) and N0 for (B). Error bars represent ± SEM. (A) TPH1 scores in samples identified as non-invasive (NI); invasive, node-nega-
tive (IN-); invasive, node-positive (IN+); and invasive with distant metastases (IN-Mets). (B) Human breast cancer tissue sections scored for TPH1 
were sorted as per different stages of nodal metastasis (N-stage: N0, no regional lymph node involvement; N1, Mets to movable ipsilateral nodes; 
N1a/b, Mets up to 20 mm to 4 or more nodes with extension beyond node capsule; N2-3, Mets to ipsilateral nodes that are fixed to one another or 
to other structures and to internal mammary lymph nodes). (C) Representative microarray sections stained for TPH1 from sorted groups as indicated 
below each image. Brown/red dye indicates TPH1 stain, blue is hematoxylin.Page 6 of 17
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Figure 4
Difference in 5-HT receptor isoform gene expression between non-transformed (pHMECs and MCF10A) and breast cancer cells (MCF7, MDA-MB-231 and T47D)
231 and T47D). (A) Representative RT-PCR reactions (mRNA transcripts) for indicated 5-HT receptors, in cells as indicated at the top. Human brain 
(hypothalamus) is used as a reference sample for each receptor. For primer information please see Table S1 in Additional data file 1. (B) Densito-
metric quantification (semi-quantitative) of transcript levels relative to human brain reference samples (100%). Each column represents average with 
error bars representing ± SEM of at least three independent reactions.
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expression was also lower in basal tumors (ER negative), com-
pared with luminal tumors, which are most commonly ER pos-
itive (Table 1).
Expression levels for HTR1F, 2B, 2C, 5A and 7 showed overall
increases in breast cancers. HTR2B, which is expressed in
untransformed human mammary epithelium (Figure 4), was
elevated in carcinomas and was found to increase with tumor
stage, and concomitantly was higher in lymph node-positive
tumors as compared to node-negative tumors (Table 1). This
observation was supported by a study of HMECs, showing c-
Myc transformation induced an increase in HTR2B expression
(Table 1). Similar to HTR2B, HTR2C showed an increase in
expression with tumor stage. The HTR2C pattern was in
accord with the increased expression observed in human
breast cancer cell lines (Figure 4). Analogously, HTR2C
expression was found to be higher in metastatic and Her2/
neu-overexpressing tumors. The expression of HTR7
increased with tumor grade, and was higher in p53-mutated
tumors (Table 1). This observation also was supported by a
study of HMECs, showing H-Ras transformation induced
increases in HTR7 expression. Other 5-HT receptor expres-
sion changes in breast cancers included HTR1F (higher in
Table 1
Modification of 5-HT receptor expression with human breast cancer status - Oncomine study
Study Type Receptor Type Variable Direction of Change P-value
(T-test)
Oncomine data source
Tumor grade/stage HTR2B Normal vs Breast 
Carcinoma
Higher in Cancer 0.002 Richardson et. al. [77]
Tumor stage N0-N3 Increase with stage 0.006 Bittner et. al. [78]
HTR2C Tumor stage N0-N3 Increase with stage 0.009 Yu et. al. [79]
HTR7 Grade I to III Increase with grade <0.0001 Ivshina et. al. [80]
0.0001 Miller et. al. [81]
<0.01 Ginestier C et. al. [82]
More aggressive vs Less 
aggressive breast cancers
HTR1F 5 yrs recurrence- vs 5 yrs 
recurrence+
Higher in recurring tumors 0.005 VantVeer et. al. [83]
HTR2B Lymph node- vs Lymph 
node+
Higher in lymph node + 0.006 Chin et. al. [84]
HTR2C Primary vs Metastatic 
tumors
Higher in metastatic 0.001 Bittner et. al. [78]
Her2/neu- vs Her2/neu+ Higher in Her2/neu+ 0.00057 Minn et. al. [85]
0.002 Hess KR et. al. [86]
HTR5A P53-mutant vs p53-WT Higher in p53-mutant <0.0001 Miller et. al. [81]
HTR7 P53-mutant vs p53-WT Higher in p53-mutant 0.008 Miller et. al. [81]
Steroid receptor status HTR1F ER+ vs ER- Higher in ER+ 0.0001 Sotiriou et. al. [87]
HTR2B ER+ vs ER- Higher in ER+ 0.00014 Wang et. al. [88]
0.0004 Sotitiou et. al. [87]
0.00014 Desmedt et. al. [89]
Luminal vs Basal Tumors Lower in Basal (ER-) <0.0001 Farmer et. al. [90]
HTR4 ER+ vs ER- Higher in ER+ 0.001 Chi et. al. [84]
HTR7 ER+ vs ER- Higher in ER+ <0.0001 VanderVijer et. al. [91]
0.00087 Bittner et. al. [78]
Human Mammary Cell 
lines
HTR2B HMEC-Normal (GFP) vs c-
Myc transformation
Higher in c-Myc 
transformed cells
0.001 Bild AH et. al. [92]
HTR7 HMEC-Normal (GFP) vs 
activated H-Ras
Higher in H-Ras cells 0.00028 Bild AH et. al. [92]
Receptor mRNAs encoding 5-HT1F (HTR1F), 5-HT2B (HTR2B), 5-HT2C (HTR2C), 5-HT4 (HTR4), 5-HT5A (HTR5A) and 5-HT7 (HTR7) sorted as per 
tumor stage/grade, ER status, tumor aggressiveness and human mammary cell line transformation. Abbreviations: (ER+) - Estrogen Receptor 
Positive, (ER-) - Estrogen Receptor Negative. (HMEC) - human mammary epithelial cells.Page 8 of 17
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The variety of examples showing aberrant expression of 5-HT
receptors in breast cancers suggests that multiple modifica-
tions of 5-HT signaling can contribute to the loss of tissue
homeostasis during tumor progression.
5-HT-induced apoptosis and morphological transition
Our previous studies on 5-HT physiology in mammary gland
cells revealed the critical roles of 5-HT in regulating epithelial
homeostasis during involution, which is characterized by epi-
thelial tissue regression [5-7,40,41]. One expected effect of
elevated 5-HT activity in the normal breast is widespread
apoptotic cell death. Hence, we tested the effects of 5-HT on
apoptosis in mammary epithelial cells. The pHMEC and
MCF10A cells, as expected, showed significant increases in
active caspase 3 staining when treated with 5-HT, as com-
pared to untreated controls (Figure 5A). In contrast, all of the
breast cancer cell lines were highly resistant to 5-HT-induced
apoptosis under similar experimental conditions.
In response to 5-HT, MDA-MB-231 cells underwent dramatic
changes in their morphological phenotype, assuming exagger-
ated fibroblastic spindle morphologies (Figure 5B). In the
presence of 5-HT, the MDA-MB-231 cells projected long axial
appendages, which inconsistently contacted neighboring
cells, sometimes crossing cells without apparent interactions.
Previously, similar changes in morphology of MDA-MB-231
cells have been associated with exaggerated motility and inva-
siveness [42,43]. No similarly obvious phenotypic effects of 5-
HT treatment were observed in MCF10A, pHMEC, T47D or
MCF7 cells, suggesting that this response to 5-HT may be lim-
ited to the most aggressively-transformed breast cancer cells,
which have undergone an epithelial-mesenchymal transition
(Figure 5B).
Serotonin inhibits growth of untransformed human 
mammary epithelial cells via the 5-HT7 receptor
Because breast cancer cells were resistant to 5-HT-induced
apoptosis, we decided to explore its impact on proliferation in
these cells. Treatment with 5-HT for 36 h (in serum-containing
medium) resulted in significant inhibition of proliferation in both
pHMECs (approximately 55%) and MCF10A (approximately
37%), compared to untreated controls (Figure 6Ai and 6ii).
This observation was verified by a standard trypan blue assay
under similar experimental conditions [see Figure S5 in Addi-
tional data file 1]. Methysergide (MS), a broad spectrum 5-HT
receptor antagonist, attenuated growth inhibition by 5-HT in
pHMECs and MCF10A (Figure 6Ai and 6ii). Our previous
study showed that mammary epithelial cells express the 5-HT7
receptor [6] and stimulation of this receptor results in cyclic
AMP (cAMP)-mediated activation of both protein kinase A
(PKA) and p38 mitogen activated protein kinase (p38 MAPK)
[7]. Treatment of MCF10A cells with a 5-HT7 antagonist
(SB269970 [SB]) resulted in near complete extinction of 5-
HT inhibition of proliferation (Figure 6Aiii). In addition, specific
inhibition of p38 MAPK blocked the inhibition of proliferation
(Figure 6Aiv), however PKA inhibition had no significant effect
on proliferation. These data suggest that 5-HT7-mediated p38
MAPK activation may, in part, be responsible for growth inhib-
itory actions of 5-HT in mammary epithelial cells.
Breast cancer cells are refractory to the growth inhibitory 
response to 5-HT
It seemed paradoxical that breast cancer cell lines had an
increased capacity for 5-HT biosynthesis (Figure 1), while 5-
HT acted as a growth-inhibitor in mammary epithelial cells (Fig-
ure 6A). The juxtaposition of these findings suggested that the
breast cancer cells might be resistant to growth inhibition by
5-HT. Hence, we tested the effect of 5-HT on proliferation of
breast cancer cells. Confirming the previous result, 5-HT, in a
concentration dependent manner, inhibited proliferation of
mammary epithelial cells (pHMECs and MCF10A) (Figure
6B). However, breast cancer cells (T47D and MDA-MB-231)
responded differently to 5-HT. The T47D cells were resistant
to 5-HT, which required five- to ten-fold higher concentrations
to show growth inhibition (Figure 6Bi). However, MDA-MB-
231 cells were not only resistant to growth inhibition, but also,
were significantly stimulated by 5-HT at low concentrations
(Figure 6Aii). The altered response of MDA-MB-231 cells to 5-
HT was seen in spite of the presence of strong expression of
the HTR7 (Figure 4A and 4Bvi). To determine whether differ-
ences in cell death could account for the effects of 5-HT on
proliferation, we measured lactate dehydrogenase (LDH) lev-
els in the media, which is indicative of lysed/dead cells. In both
the MCF10A and MDA-MB-231 cells, the LDH levels in the
media remained unchanged by 36 h after 5-HT treatment [see
Figure S6 in Additional data file 1]. At later time points (72 h,
see Figure 5), there was substantial apoptosis in the untrans-
formed (i.e., MCF10A) cells and pHMECs, which implied that
these cells underwent growth arrest early, followed by apopto-
sis if 5-HT signaling was sustained.
Altered 5-HT7 signaling in human breast cancer cells
Given that growth inhibition by 5-HT occurs through the 5-HT7
receptor, resistance to growth inhibition in breast cancer cells
could be explained by: 1] a loss of 5-HT7 receptor expression
(Figure 4A and 4Bvi), 2] expression of 5-HT receptors that
counteract 5-HT7 (that is, Gi-coupled), (Figure 4A, Bii and
6Biii) or 3] changes in signaling downstream of 5-HT7; and
these possibilities are not mutually exclusive. Expression of
HTR7 in MDA-MB-231 cells was greater that in pHMEC and
MCF10A, yet MDA-MB-231 cells showed significant differ-
ences in their response to 5-HT (Figure 6Bii). Therefore, we
sought to determine whether Gs-coupled signaling, which is
downstream of 5-HT7, was altered in MDA-MB-231. As previ-
ously described [6], MCF10A cells showed a 5-HT concentra-
tion-dependent increase in cAMP accumulation (Figure 6Biii).
In MDA-MB-231 cells, the maximum cAMP activation wasPage 9 of 17
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Figure 5
5-HT influence on apoptosis and morphological transition in breast cells. (A) Staining for apoptosis marker cleaved caspase-3 (green), counter-
stained for nuclei (blue) for the indicated cells with or without 5-HT (7.5 × 10-4 M) treatment for 72 h in serum free media. (B) Phase-contrast images 
of the indicated cells with or without 5-HT (7.5 × 10-4 M) treatment for 72 h. Arrowheads point to appendages at intersections between adjacent 
cells.
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Figure 6
Growth inhibition by 5-HT in non-transformed human mammary epithelial cells is via 5-HT7 recepto, r and breast cancer cells are refractory to growth inhibition by 5-HT
inhibition by 5-HT. (Ai-iv) Proliferation assay (MTT) for detecting growth of primary human mammary epithelial cells (pHMECs) (Ai) and MCF10A 
(Aii-iv) after a period of 36 h following indicated treatments. Graphs are plotted as percent change from control (Ctrl - untreated) group. Error bars 
represent ± SEM. ***P < 0.001 (one-way ANOVA). (Ai and Aii), depict indicated cells treated with 5-HT (7.5 × 10-4 M) in presence or absence of 
broad-spectrum 5-HT receptor antagonist methysergide (MS) (60 μM). (Aiii) depicts MCF10A cells treated with 5-HT (7.5 × 10-4 M) in presence or 
absence of specific 5-HT7 receptor antagonist SB 269970 (SB) (80 μM). (Aiv) depicts MCF10A cells treated with 5-HT (7.5 × 10-4 M) in presence 
or absence of specific inhibitors of signaling proteins p38 MAPK (SB203580 [p38I]) (20 μM) and PKA (H89 [PKAI]) (10 μM). (Bi-ii) depict a prolif-
eration assay (MTT-viable count) for detecting cell growth after 36 h of treatment with indicated 5-HT concentrations. Graphs are plotted as percent 
change from respective controls (untreated group). Error bars represent ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Two-way ANOVA). (Bi) 
depicts comparison of pHMECs (grey bars) and T47D (black bars) cells response to indicated 5-HT concentrations. (Bii) depicts comparison of 
MCF10A (grey bars) and MDA-MB-231 (black bars) cells response to indicated 5-HT concentrations. (Biii) depicts measurements of intracellular 
cAMP accumulation in MCF10A (grey squares and line) and MDA-MB-231 (black triangle and line) cells in response to 5-HT stimulation as indi-
cated. Error bars in Biii represent ± SEM. ** P < 0.01, *** P < 0.001 (Two way ANOVA).
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gressive decline in cAMP to levels below that of controls. Peak
cAMP accumulation was identical in both cells (Figure 6Biii).
These data imply altered signaling events associated with 5-
HT7.
Discussion
Regulation of mammary epithelium involves processes such as
epithelial proliferation, invasion of stroma and epithelial regres-
sion accompanied by extracellular matrix remodeling. Dysreg-
ulation of such epithelial regulatory mechanisms are critically
involved in the progression of breast cancers [17,18,42,44-
46]. The series of studies reported here were undertaken to
establish whether there are functionally-relevant associations
between local mammary 5-HT signaling and breast cancers.
The simple expedient of identifying serotonergic elements by
profiling of either mutations or gene expression was not appli-
cable to this problem because of the complexity of the 5-HT
receptor systems. This receptor complexity, and the multiple
mechanisms by which the ligand concentration is regulated,
make it possible for either normal or cancer cells to evolve
completely different sets of signaling interactions to achieve
common ends. This characteristic amounts to convergent evo-
lution of signaling among cancers, and it required us to use a
hypothesis-driven set of approaches, combined with hypothe-
sis-driven data mining.
In our previous studies, we showed that the mammary epithe-
lium expresses the TPH1 gene, which is induced during preg-
nancy, lactation and milk stasis at the onset of involution [5].
Here we have shown by immunostaining that TPH1 is present
primarily in the epithelial tissue of mammary glands. An early
finding that piqued our interest in the 5-HT system in human
breast cancer was the observation that representative breast
cancer cell lines showed significantly elevated TPH1 tran-
script and protein levels. These results were confirmed by
staining for TPH1 protein, which showed uniform and elevated
TPH1 expression among cancer cell lines. The shift of TPH1
gene expression from the normal tightly-regulated in vivo pat-
tern to a state of homogeneous overexpression in breast can-
cer cells was reminiscent of the general up-regulation of ER in
estrogen-sensitive breast cancer cells [47,48]. Whereas ER
and PR expression are positively correlated in breast cancers
an interesting observation was no effect of PR status on TPH1
levels. However, it has been reported that PR can be inde-
pendently regulated in breast cancers [49,50]. Hence, it is
likely that TPH1 is regulated by ER independent of PR status.
Since TPH1 is rate limiting for 5-HT synthesis in mammary epi-
thelial cells, as in other systems [6], breast cancer cells syn-
thesize excess 5-HT, which they may use to support their
growth advantages.
To gain insights into the nature of the 5-HT system in human
breast tumors, we used tissue microarray and data-mining
approaches. Increased TPH1 expression in cancer cell lines
was confirmed on the microarray specimens. An important
insight was the observation that there was not a simple linear
association between TPH1 expression and cancer stage.
Although TPH1 expression was suppressed in primary tumors
at early stages, it was increased later in progression. Corre-
spondingly, all of the tissue microarray specimens were har-
vested from the primary tumor sites of cancers at different
stages, but the breast cancer cell lines, which expressed ele-
vated TPH1, were all established from metastasized cells.
Therefore, the rebound of TPH1 expression associated with
progression may result in metastatic cells that express the
highest levels of TPH1.
Carcinogenesis is a complex multistep process, occurring
hand-in-hand with metastatic progression. For a normal epi-
thelial cell, there are many internal and external checks and
balances that guard against transformation and progression,
including cell senescence, apoptosis, appropriate stress
responses, and dependence on growth factors and differenti-
ating agents [3,51]. The growth inhibitory effect of 5-HT in the
non-transformed mammary epithelium is mediated, in part,
through 5-HT7 receptor signaling. The growth suppression
response to 5-HT is supported by our previous observations in
TPH1-/- mice, which showed accelerated mammary growth
upon prolactin stimulation, and impaired regression during
milk stasis [5].
There was a wide variety of changes in 5-HT receptor expres-
sion among the cancer specimens and database results. The
convergent nature of cancer evolution, in which there are sev-
eral routes for cancer cells to take while they accumulate
advantageous physiological alterations, provides a context for
understanding the diversity of these changes. Down-regula-
tion of 5-HT7 (Gs-coupled), which mediates growth inhibition
in untransformed cells, is one route to gain a growth advan-
tage. This particular alteration was seen in MCF7 and T47D
cells, and in ER negative and p53-wildtype tumor specimens.
Other routes to achieve growth advantage include a) suppres-
sion of 5-HT7 action through induction of Gi-coupled recep-
tors, such as 5-HT1E and 1F; b) induction of growth stimulatory
5-HT2C (Gq/11-coupled) [52,53] (observed in MCF7, T47D
and in human breast tumors); and c) downregulation of 5-HT
synthesis itself, as observed in early stages of primary tumor
growth. An important observation was the identical 5-HT
receptor expression pattern in both examples of untrans-
formed cells (MCF10A and pHMECs). This indicates that in
untransformed mammary epithelial cells, 5-HT receptor
expression is under tight control, whereas the control of 5-HT
receptor expression was aberrant in all breast cancer cells.
Sonier et al., [54] previously reported expression of 5-HT2A in
MCF7 cells, but we did not observe expression of this recep-
tor in either MCF7 or other breast cancer cells. Given the
degree to which receptor expression is labile in breast cancer
cells, it is conceivable that the subline in their lab is different
from the cells we received from ATCC.Page 12 of 17
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eration rates in MDA-MB-231 cells and promoted obvious
morphological changes. Similar phenotypic changes have
been correlated with induction of a highly invasive behavior in
these cells [42,43].
Proliferative actions of 5-HT are not unprecedented and have
been reported to be crucial for liver regeneration [55]. Consid-
ering that sustained exposure to 5-HT induces quiescence
and apoptosis in untransformed mammary epithelial cells, the
response of MDA-MB-231 cells represents a major change in
the way these cells interpret the 5-HT signal. This proliferative
effect of 5-HT occurs in spite of the continued expression of
the 5-HT7 receptor, but we have not yet been able to attribute
the growth-stimulatory effect to a single 5-HT receptor. The
failure of 5-HT to cause growth inhibition and cell death in
MDA-MB-231 cells may be attributable to altered downstream
5-HT7 signaling. Changes in cAMP dynamics similar to those
we observed in MDA-MB-231 cells have been linked to a
switch from growth inhibition to growth stimulation in other
cells [56-61].
Although some of the normal physiological actions mediated
by 5-HT7 such as anti-proliferation and pro-apoptosis would
inhibit tumor progression, it is not a simple matter that 5-HT7
is uniformly tumor-suppressing. Other actions mediated by 5-
HT7 can enhance tumor progression. Among these is the dis-
ruption of cell-to-cell junctions [6,7], which provides an impor-
tant physiological advantage during invasion and metastasis.
Tight junctions have been shown to restrain tumorgenesis, and
disrupting tight junctions and other static cell junctions is
imperative for tumor growth and invasion [62,62-67].
Figure 7
Model of a working hypothesis for 5-HT influences on breast cancer progressioni  t i  f r 5- T influences on breast cancer progres ion. 5-HT is a tumor-suppressing signal in non-transformed breast cells 
and early stage breast cancers, so early tumor growth relies on reductions in TPH1 expression. During tumor progression, cells acquire genetic or 
epigenetic alterations in 5-HT signaling which then make them resistant to suppressive 5-HT actions and favor tumor-promoting actions (e.g., 
dynamic cell junctions and cell shedding), as well as acquisition of new receptors and functions (e.g., stimulated proliferation and epithelial-mesen-
chymal transition). The figure is inspired by the image in [69].Page 13 of 17
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of positive and negative consequences, cancer cells cannot
simplify their environment by avoiding 5-HT signaling com-
pletely. Apart from the fact of endogenous epithelial 5-HT bio-
synthesis, cancer cells receive 5-HT signaling from at least
three outside sources: neighboring normal breast tissue, nor-
mal blood circulation, and hemostatic plaques within tumors
(platelet activation and 5-HT release - an essential part of sta-
bilizing the tumor vasculature) [68]. Consequently, there are
advantages for breast cancer cells to be gained from altering,
rather than avoiding, 5-HT signaling. Presumably, these advan-
tages explain why TPH1 expression does not simply continue
to decline to zero in advanced cancers, and is commonly ele-
vated in the most highly-transformed cancer cells. Analogous
nonlinear associations with breast cancer progression have
been reported in the TGF-β system, which is also generally
cytostatic in normal cells but advantageous in advanced can-
cers [69,70].
While the epithelial cells of breast cancer may be important
targets of 5-HT, it is also likely that stromal elements, including
connective tissue, adipose, infiltrating blood cells, and vascu-
lar elements, are regulated by 5-HT synthesized in breast can-
cers. The discrepancy between the 5-HT receptor expression
profiles of primary mammary epithelial cells (5-HT1D,2B,3 and 7)
and in normal whole gland tissue (5-HT1B,1D,1F, 2A, 2B,3,5A and
7, Oncomine database) suggests that a subset of 5-HT recep-
tors (5-HT1F,2A,5A) are expressed in non-epithelial elements
(connective tissue, myopepithelium, blood cells, adipose tis-
sue, vasculature). Some of these extra-epithelial tissues are
well known targets of 5-HT (blood vessels and adipose), and
others, such as the connective tissue stroma, have not yet
been studied. A new study [71] has shown that 5-HT is an
important physiological suppressor of osteoblast growth and
bone mineralization. Therefore, bone, to which breast cancers
preferentially metastasize, may use breast cell-derived 5-HT as
an important extra-epithelial target tissue.
Our previous [5-7] and current results are summarized (Figure
7) as follows: a) physiological responses to 5-HT include
some that are tumor-suppressing (growth inhibition and apop-
tosis) and others that are tumor-promoting (junctional break-
down, cell shedding) and because of the growth suppression
actions, early tumor growth relies on reductions in TPH1
expression and 5-HT synthesis, and b) as the tumors progress,
cells acquire alterations in the 5-HT signal, thus developing
resistance to the tumor-suppressive aspects of 5-HT (growth
inhibition and apoptosis), while retaining and favoring tumor-
promoting actions. These effects are further enhanced by
increasing TPH1 levels and acquisition of new tumor promot-
ing-activities (cell proliferation, survival, epithelial-mesenchy-
mal transition phenotype). Fully optimized 5-HT signaling in
cancers results in tumors in which 5-HT is used to promote
growth, invasiveness, angiogenesis and other patho-physio-
logical effects. While this understanding may need many
refinements, it is further supported by the overall trend toward
increased complexity of 5-HT receptor expression in associa-
tion with aggressive tumors, which suggests beneficial influ-
ences of 5-HT on tumor progression.
Importantly, we believe the implications of understanding 5-HT
physiology extend beyond breast cancers. This is based on
reports indicating important roles of 5-HT in the cancers of
skin, gut, brain, lung, prostate, liver, and pancreas [20-
23,27,28]. Duct systems that are lined by epithelia and require
homeostatic regulation represents a common denominator
among these organ systems. In some of these organs, like
breast and liver, 5-HT has been implicated in homeostatic reg-
ulation of secretory ducts [19,29,72].
Conclusions
Although cancers generally are clonal and may rely on self-
renewing stem cells over the long term [3,45,73-76], any given
tumor must become heterotypic if it is to reach a substantial
size and pathophysiologic complexity. The cancer consists of
a community of cells that contribute different pathophysiologi-
cal properties. The heterotypic nature of a cancer is responsi-
ble for its ability to adapt to a changing microenvironment
during progression through invasiveness and metastasis.
Among the different cell types within a cancer, there are pre-
sumably differences in the components and functionality of the
5-HT system. Such differences include cells with a greater or
lesser ability to synthesize 5-HT, and cells with different com-
plements of receptors. While this heterotypic 5-HT physiology
in breast tumors may create a great deal of complexity, it is
possible that future studies will identify common features or
weak links in the 5-HT system of breast cancers, which can be
exploited therapeutically. The inherent druggability of 5-HT
systems makes it reasonable to assume that treatments target-
ing these systems could achieve sufficiently positive therapeu-
tic indices to justify their uses in cancer.
It would be premature to suggest that studies reported here
are sufficient to establish the prognostic or therapeutic value
of the breast cancer TPH1/5-HT system. However, an early
prediction from our studies is that tumors in which TPH1 is sig-
nificantly downregulated will have not yet gained resistance to
5-HT or reached metastatic stages. Therefore, TPH1 down-
regulation may indicate a better prognosis. Through further
studies on the breast 5-HT system we expect to improve our
understating of its role in breast cancer.
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